New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04
Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis erzielt im zweiten Quarta…
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis erzielt im zweiten Quarta…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Scembl…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Latest analysis of No…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis atrasentan Phase III data show clinica…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Mon, 05/05/2025 – 13:04…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Mon, 05/05/2025 – 13:04…
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
…
